PD-1 在 美国癌症研究协会年会 上引发轩然大波。
PD-1 Pandemonium at the American Association for Cancer Research Annual Meeting.
机构信息
Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
出版信息
Oncologist. 2019 May;24(5):571-573. doi: 10.1634/theoncologist.2019-0281.
Abstract
This editorial describes the results of discussions between the U.S. FDA Oncology Center of Excellence and members of six pharmaceutical companies—a forum aptly named PD‐1 Pandemonium—regarding development and regulatory approvals of immune checkpoint inhibitors.
摘要
这篇社论描述了美国 FDA 肿瘤卓越中心与六家制药公司成员之间的讨论结果——这是一个恰如其名的 PD-1 大混乱论坛——讨论了免疫检查点抑制剂的开发和监管批准。
相似文献
1
PD-1 Pandemonium at the American Association for Cancer Research Annual Meeting.PD-1 在 美国癌症研究协会年会 上引发轩然大波。
Oncologist. 2019 May;24(5):571-573. doi: 10.1634/theoncologist.2019-0281.
2
Making precision oncology the standard of care.使精准肿瘤学成为护理标准。
Lancet Oncol. 2017 Jul;18(7):835. doi: 10.1016/S1470-2045(17)30474-6.
3
Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.社论：免疫检查点分子与癌症免疫疗法
Front Immunol. 2018 Dec 5;9:2878. doi: 10.3389/fimmu.2018.02878. eCollection 2018.
4
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.癌症的免疫检查点阻断疗法：FDA 批准的免疫检查点抑制剂概述。
Int Immunopharmacol. 2018 Sep;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub 2018 Jul 2.
5
Dostarlimab: First Approval.多斯塔利单抗：首次获批。
Drugs. 2021 Jul;81(10):1213-1219. doi: 10.1007/s40265-021-01539-5.
6
Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?疾病进展后再次使用PD-1/PD-L1抑制剂进行激发试验是否可行？
Immunotherapy. 2018 Apr;10(5):345-347. doi: 10.2217/imt-2017-0180.
7
The FDA Oncology Center of Excellence and precision medicine.美国食品和药物管理局肿瘤卓越中心与精准医学
Exp Biol Med (Maywood). 2018 Feb;243(3):308-312. doi: 10.1177/1535370217740861. Epub 2017 Nov 6.
8
Keeping Expectations in Check With Immune Checkpoint Inhibitors.用免疫检查点抑制剂控制期望。
J Clin Oncol. 2018 Jun 10;36(17):1654-1657. doi: 10.1200/JCO.2017.76.2146. Epub 2018 Jan 25.
9
PDL-1/PD1 inhibitors: antibody or antinobody?程序性死亡受体配体1/程序性死亡蛋白1抑制剂：抗体还是抗抗体？
Future Oncol. 2017 Aug;13(19):1669-1671. doi: 10.2217/fon-2017-0215. Epub 2017 Aug 23.
10
Immune checkpoint inhibitors.免疫检查点抑制剂。
J Cell Biol. 2019 Mar 4;218(3):740-741. doi: 10.1083/jcb.201810035. Epub 2019 Feb 13.
本文引用的文献
1
Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.针对既往治疗的晚期非小细胞肺癌的 PD-1/PD-L1 通路免疫治疗药物的疗效和安全性比较：一项贝叶斯网状荟萃分析。
Crit Rev Oncol Hematol. 2019 Oct;142:16-25. doi: 10.1016/j.critrevonc.2019.07.004. Epub 2019 Jul 10.
2
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.接受派姆单抗作为一线治疗的晚期 Merkel 细胞癌患者的持久肿瘤消退和总生存期。
J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.
3
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?在联合化疗的情况下，哪种免疫疗法是晚期鳞状非小细胞肺癌的最佳选择：抗 PD-1 还是抗 PD-L1？
J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6.
4
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.试验观察：PD1/PDL1免疫检查点抑制剂的临床试验概况
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210.
5
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.PD-L1 免疫组织化学在真实临床样本中的可比性研究：Blueprint 阶段 2 项目的结果。
J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.
6
A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer.一项比较抗程序性死亡蛋白1（Anti-PD-1）与抗程序性死亡配体1（Anti-PD-L1）在非小细胞肺癌中疗效和安全性的网状Meta分析。
J Cancer. 2018 Mar 10;9(7):1200-1206. doi: 10.7150/jca.22361. eCollection 2018.
7
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.寻找预处理 NSCLC 患者中最佳的免疫检查点抑制剂：纳武利尤单抗、帕博利珠单抗和阿替利珠单抗的间接比较。
Int J Cancer. 2018 Mar 15;142(6):1277-1284. doi: 10.1002/ijc.31136. Epub 2017 Nov 14.
8
Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.经验教训：小分子靶向肿瘤药物的剂量选择。
Clin Cancer Res. 2016 Jun 1;22(11):2630-8. doi: 10.1158/1078-0432.CCR-15-2646.
9
Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.小分子肿瘤药物的剂量发现：贯穿整个开发生命周期的优化。
Clin Cancer Res. 2016 Jun 1;22(11):2613-7. doi: 10.1158/1078-0432.CCR-15-2643.
10
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.评估提交至大型年度肿瘤学会议的临床试验摘要的最终发表情况。
Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.
Zotero 插件